Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol

The effects of labetalol, metoprolol, and placebo on pulmonary function and their interaction with isoproterenol were evaluated in 18 patients with reversible bronchial asthma [isoproterenol-induced increase in forced expiratory volume in 1 second (FEV1) of greater than or equal to 15%]. Two dose le...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of asthma Vol. 23; no. 5; p. 251
Main Authors Falliers, C J, Vincent, M E, Medakovic, M
Format Journal Article
LanguageEnglish
Published England 1986
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:The effects of labetalol, metoprolol, and placebo on pulmonary function and their interaction with isoproterenol were evaluated in 18 patients with reversible bronchial asthma [isoproterenol-induced increase in forced expiratory volume in 1 second (FEV1) of greater than or equal to 15%]. Two dose levels of each medication were studied (on consecutive days), with the lower doses of these drugs given randomly. When the lowest values during the 2-hour postdrug evaluation period were considered, FEV1 significantly increased (10.9%; 15.4%) following labetalol (200 and 400 mg, respectively), significantly decreased (-11.2%; -5.4%) after metoprolol (100 and 200 mg, respectively), and was unchanged after placebo. The effects of the three treatments on forced vital capacity (FVC) and maximal midexpiratory flow (MMEF) were qualitatively similar to those observed in FEV1. When isoproterenol was administered following labetalol (200 and 400 mg), FEV1 further increased with a resulting combined increase of 18.9 and 19.7%, respectively, indicating an additive interaction. The effect of isoproterenol was blunted by metoprolol (100 and 200 mg) (p less than 0.01, difference from the effect observed after labetalol and isoproterenol), indicating antagonistic interaction between these two drugs. Labetalol may be a safer antihypertensive than metoprolol in patients with concomitant bronchial asthma.
ISSN:0277-0903
1532-4303
DOI:10.3109/02770908609073169